Enhance your practice with CMEand tools that focus on the managementand treatment of patients with cancer.
Moving Toward Biomarker-Driven Care in Bladder Cancer
Benjamin Garmezy, MD
Optimizing Patient Selection for Perioperative Therapy in Bladder Cancer
Key Questions Shaping Chemotherapy-Free Treatment in Mantle Cell Lymphoma
Jonathon B. Cohen, MD, MS
Reducing Cardiovascular Risk in Adult Survivors of Childhood Cancer
Stephanie Dixon, MD, MPH
Supportive Care During and After CLL Treatment: What to Prioritize
Kerry A. Rogers, MD
A Look at WCLC 2026: Pivotal Trials and Emerging Directions
Triparna Sen, PhD
Making the Most of WCLC 2026: A Guide for Early-Career Professionals
Closing Gaps in CRC Screening: From Stool-Based Testing to Timely Colonoscopy
Shelina Ramnarine, PhD
David A. Johnson, MD, FACG, FACP
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Komal Jhaveri, MD, FACP
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Virginia Kaklamani, MD, DSc
Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic
September 24, 2026
06:00 PM - 07:00 PM ET
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
Saad Z. Usmani, MD, MBA
Natalie S. Callander, MD
Moving Beyond Chemotherapy in Mantle Cell Lymphoma Care
Jonathon Cohen, MD, MS
Supportive Care Before CLL Treatment: Infection Risk and Comorbidity Management
Adapting CV Risk Reduction Strategies for Cancer Survivorship
Closing the Colonoscopy Follow-Up Gap: Insights from a JNCCN Study
Peter Buch, MD, FACG, AGAF, FACP
Mallik Greene, PhD
Jordan Karlitz, MD
What's Next for Urothelial Cancer Treatment?
Myeloid Mutations in ALL: Disease Risk and Prognostic Implications
Caner Saygin, MD
How Myeloid Mutations in ALL Inform Treatment Decisions
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.